Allergy Therapeutics PLC
10 May 2006
Allergy Therapeutics plc
Director Shareholding
10 May 2006
Allergy Therapeutics plc ("the Company") announces that, on 8th May 2006, a US
Grantor Retained Annuity Trust (called the "Ignace Goethals GRAT 2001"), of
which Ignace Goethals was a Trustee, matured in favour of Mr. Goethals' three
children, each of whom is over 18. Mr. Goethals held 788,457 shares through this
vehicle since the Company's admission to AIM in 2004.
As a consequence, Mr. Goethals' ongoing beneficial holding of shares of 0.1pence
each in the Company, which include 719,349 shares held through another GRAT
(called "the Ignace Goethals GRAT 2003" which will mature in August 2008), is
1,797,912 shares.
There is no economic benefit accruing to Mr. Goethals as a result of the
maturity of the Ignace Goethals GRAT 2001.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.